Clinical Trial Update: SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

View source ↗

Summary

Clinical trial SAPHIR assesses predictive factors for persistence of adalimumab treatment after switching from reference product to Fresenius Kabi's adalimumab …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Adalimumab biosimilar Fresenius Kabi (adalimumab)
• Humira (adalimumab)

Snippet

Sponsor: Fresenius Kabi, France | Conditions: Crohn Disease, Ulcerative Colitis | Status: UNKNOWN